Q-omics provides the consensus-scored TTLL10 profile across patient tissues and cancer cell-line models. TTLL10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTLL10 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TTLL10 RNA expression shows 14,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where TTLL10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL10 survival associations across molecular data types. TTLL10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL10 RNA expression–survival associations across cancer types. High TTLL10 expression shows unfavorable associations in READ, but favorable associations in HNSC, KIRC, LUAD, LUSC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTLL10 RNA expression.
This table summarizes TTLL10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TTLL10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL10 shows lower tumor expression in KICH, LUAD and KIRP and higher tumor expression in COAD, LIHC and STAD. The KICH box plot shows higher TTLL10 RNA expression in normal versus tumor tissue (log2 FC = −0.407, t-test p < 0.001).
This table shows molecular features associated with TTLL10 in patient tissues and cancer cell lines. In patient samples, TTLL10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
